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Abstract 
 
Latent autoimmune diabetes in adults (LADA) 
Allan Gutlić 
 
Latent autoimmune diabetes in adults (LADA) is a form of diabetes with a wide range 
of phenotypic presentations. This review focuses on the best diagnostic method based 
on current studies and examines the best treatment approach once diagnosis has been 
made in patients with LADA. Based on glutamic acid decarboxylase autoantibody 
(GADA) titers it can be divided into either LADA 1 or LADA 2. The former sharing 
clinical features of DM 1 with quicker onset of insulin dependence, the latter 
resembling DM 2 with higher BMI and less need for insulin. The clinical and genetic 
heterogenuity of LADA has casued much contraversery as it has been debated wether 
or not it should be considered as a separate entity or part of a continuum between DM 
1 and DM 2. However, proper diagnosis and treatment is highly needed for this 
subgroup of patients, as they eventually have worse metabolic control and are more 
prone to DKA than DM 2 patients. The proportion of patients with LADA and DM 1 
is roughly estimated to be equal considering the fact that about 10 % of DM 2 patients 
actually belong to the LADA subgroup. With regards to this large number of LADA 
patients, screening methods are crucial for indentification, correct treatment and 
stricter metabolic control.  
 
Keywords: LADA, autoimmune, diabetes, GADA, diagnostic criteria 
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Sažetak 
 
Latentni autoimunosni dijabetes odraslih 
Allan Gutlić 
 
Latentni autoimunosni dijabetes odraslih (LADA - akronim po engleskom nazivu) je 
oblik šećerne bolesti širokog spektra fenotipa. Ovaj prikaz je usredotočen na metode 
dijagnoze temeljene na ispitivanjim i na terapijski prostup kada se dijagnoza postavi. 
Temeljem titra antitijela na dekarboksilazu glutaminske kiseline (GADA) može se 
podijeliti u LADA 1 i LADA 2. LADA 1 je sličan tipu 1 šećerne bolesti, s bržim 
nastankom ovisnosti o inzulinu dok LADA 2 klinički više liči na tip 2, uz veći indeks 
tjelsne mase i s manjom potrebom za inzulinom. Klinička i genetska hetergenost 
LADA izaziva dosta kontroverzi. Raspravlja se jesu li to različiti entiteti ili se radi o 
kontinuumu između tipa 1 i tpa 2 šećerne bolesti. U svakom slučaju, prava dijagnoza 
je nužna za ovu skupinu bolesnika jer oni postaju metabolički loše regulirani i skloniji 
su ketocidozi od onih s tipom 2 bolesti. Udio bolesnika s LADA i tipom 1 se cijeni 
ugrubo istim zbog činjenice da je oko 10 % osoba s tipom 2 šećerne bolesti u ovoj 
podskupini. Obzirom na velik broj osoba s LADA dijagnostičke metode su bitne za 
njihovu identifikaciju koja omogučuje prikladnije liječenje i striktniju metaboličku 
kontrolu.  
 
Ključne riječi: LADA, autoimunost, šećerna bolest, GADA, dijagnostički kriteriji 
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Introduction  
 
The two main types of Diabetes are type 1 and type 2 diabets. The incidence of DM 1 
is higher in children 5-7 years of age and around puberty (1). DM 1 patients often are 
leaner with insulin dependence, have lower C-peptide levels and are more prone to 
developing ketoacidosis at first time diagnosis (2). Out of the two main types, DM 2 
is by far the more prevalent one. It is now the fastest growing type and thus creating 
an even higher health burden globally, especially in developed countries but also in 
developing countries (3). Some potential reasons for this rapid growth is a general 
increase in life expectancy, improved diagnosis and faulty dietary habits with lack of 
exercise (4). LADA as an indistinctly described entity lies somewhere in between 
type 1 and 2 diabetes and has been called 1.5 diabetes. It shares a common genetic, 
immunologic and clinical characteristics with both types. This wide continuum of 
LADA represents a challenge in the diagnosis and treatment approach. There is a 
necessity to better define LADA and formulate a treatment approach. It could play a 
key role in slowing progression and improve prognosis in these patients. 
 
 
LADA is clinically more similar to type 2 diabetes but have some genetic 
characterisics in common with type 1 diabetes. Therefore it is often underdiagnosed 
and instead treated as type 2 diabetes. No clear data can be found on the global 
prevalence of LADA but an estimation based on several studies from Europe and Asia 
indicate that 3-14% of patients with DM 2 have autoantibodies and hence should be 
classified as LADA (5). Glutamic acid decarboxylase autoantibody (GADA) positive 
DM 2 patients seemed to be more frequent in northern Europe than southern Europe 
and Asia but due to the lack of clear diagnostic criteria this difference could be 
attributed to selection bias and variations in methods for diagnosis. The criteria for 
LADA are not strictly set and current standard diagnostic criteria do not exist. The 
three criteria proposed by the immunology of diabetes society are as follows:  
1. Presence of autoantibodies in plasma. 
2. Insulin independence for at least 6 months after diagnosis 
3. An onset of disease after 30 years of age.  
The second criteria above distinguishes LADA from DM 1. This criteria is dependent 
on which stage of disease the patient is diagnosed at and when the physician decides 
	 4	
to initiate insulin therapy making it subjective. The accuracy of the age cut off in the 
third criteria is also questionable becasue autoantibody status in a study with DM 2 
children was similar in frequency compared to DM 1 children (6).  
 
By implementing these criterias in all studies, comparisons can be made with more 
certainty. The heterogeneity of diabetes still poses a problem for classification of 
LADA since not all subgroups of patients might express the same phenotype 
according to antibody postivity.  
 
 
Genetic  similarities 
The role of genetics in diabetes is a perplexing issue invloving genetic and 
environmental factors. External environmental influences can affect incidence rates 
because differences are seen in rates among countries. Higher rates are observed in 
monozygotic twins compared to dizygotic confirming that internal genetics are 
partially responsible for disease development. The complex interaction of these two 
factors have made it difficult to establish exact predictors and mechanisms leading to 
acquisition of the disease. Many genes have been discovered for DM 1, while those 
for DM 2 have initially been harder to find. Recent advances in genotyping by GWAS 
have gain more insight on the genes associated with DM 2. Unfortunatley the interest 
in finding specfic genes for LADA is low and no single genes exist that are found 
only in LADA. Instead an admixture of genes from both DM 1 and DM 2 is seen. To 
understand the genetic composition of LADA we must first separately consider the 
genes responsible for DM 1 and DM 2 respectively. 
 
The major high risk genes involved in pathogenesis of DM 1 have been known for a 
longer time and they are found on HLA class II. They are all HLA-DR/HLA-DQ 
haplotypes, namely DRB1, DQA1 and DQB1. The two combinations of alleles that 
confers the greatest risk for DM 1 are called DR3 and DR4. Being heterozygos for 
these two alleles contributes to the highest risk of acquring DM 1 (7). The HLA locus 
is generally thought to be responsible for approximately 50 % of genetic causes for 
developing DM 1. The number of studies on LADA and the genetic correlation to DM 
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1 are few but the HLA II class is implicated to play a role in LADA as well (8-10). 
Another locus that attributes to risk in both phenotypes is the INS locus (11, 12). 
 
A large number of new genes associated with DM 2 have recently been found with 
the help of GWAS. The most important of these with the greatest impact in DM2 
pathophysiology is a transcription factor called TCF7L2, a member of the Wnt 
signaling pathway (13).  A global meta-analysis investigating the association of DM 2 
and TCF7L2 showed a pooled odds ratio of 1.46 (CI, 1.42-1.51) in patients versus 
controls. Overexpression of TCF7L2 in islet cells is seen in DM 2 and is linked to 
diminished insulin secretion (14). The impact of TCF7L2 has been shown to be of 
equal significance in LADA (15). Though the impact in LADA seem to be higher in 
patients that have a lower BMI (16). Patients with low GADA titers are more prone to 
have a DM 2 phenotype (LADA 2) and as expected the frequency of TCF7L2 is 
higher in this subgroup of patients (17). 
 
 
Clinical features 
 
Newly diagnosed type 1 diabetics are usually have a lower BMI and systolic blood 
pressure than type 2 diabetics (18). Due to minimal or absent insulin secretion type 2 
diabetics are more prone to present with diabetic ketoacidosis. The lack of insulin 
forces the body to break down fatty acids through beta oxidation instead of glucose 
thus creating ketones in the process. LADA falls somewhere in between these two, 
with the presentation depending on autoantibody status, especially the presence of 
glutamic acid decaboxylase antibodies (GADA). A study on the effect of GADA titers 
in LADA patients was done and three groups of patients were compared (19). Those 
with high titers (>17.2U/mmol), low titers (>1U/mmol and <17.2Ummol) and a 
GADA negative group of type 2 diabetics. There was a lower incidence of high BMI, 
hypertension, high LDL and low HDL in the group with high GADA titers than in the 
other two groups which had similar results (19). These differences in clinical profile 
between LADA with high and low GADA titers has led them to be sub-classified as 
LADA 1 and LADA 2 respectively. Zampetti et al. looked at the concomitant 
probability of other autoimmune diseases comparing the same three groups but with 
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different cut-off values for high and low GADA titers. They found a significantly 
increasing trend of thyroid autoimmunity in both men and women in the high GADA 
titer group (20). The odds ratio for males when comparing the high titer group with 
the T2DM group was 8.9 CI (4,1-19.3) and females 3.6(1.8-6.8).  
 
 
Diagnosis and screening 
 
According to WHO diabetes can be diagnosed by having symptoms of diabetes 
(polyphagia, polyuria, polydipsia and weight loss) and a fasting plasma glucose (FPG) 
of  ≥7.0mmol/l, a random venous glucose of ≥11.1mmol/l or a plasma glucose of 
≥11.1mmol/l 2 hours after ingesting 75mg anhydrous glucose in an oral glucose 
tolerance test (OGTT) (21). With the lack of diabetic sympotms it is essential to 
perform a second confirmatory glucose test. Until recently the recommendation was 
to refrain from using Hemoglobin A1C (HbA1C) in diagnosis but WHO have in 2011 
accepted the use of it as well. A HbA1C of ≥48mmol/l (6.5%) is positive and reflects 
the glucose status in the body the last three months. There are no clear diagnostic 
criteria for LADA since it is a widely heterogenous disease entity. There is a need for 
clinical diagnostic guidlines to correctly diagnose and treat LADA patients because of 
the current lack of awareness among physicians leading to patients not being treated 
optimally.  As mentioned earlier not all LADA patients progress to insulin deficiency 
at the same rate. They can either be LADA 1 or 2 and their progression can be 
predicted by autoantobodies (especially GADA) and monitored with C-peptide levels. 
Screening for autoantibodies in non-insulindependent adults can be rather costly if 
done on every single patient. To avoid screening all type two diabetics with GADA it 
is better to classify them according to probablility of having LADA before performing 
antibody testing. Currently it is common to screen suspected LADA patients for 
autoantibodies solely based on a BMI≤25. Given the increasing prevalence of obesity 
in general it is now even less accurate to use only BMI when deciding if autoantibody 
screening is necessary. Therefore five clinical screening criterias have been set by 
Fourlanos et al (22). The five criteria focus on an age of onset < 50 years, BMI≤25, 
acute symptoms of diabetes, personal history of DR3/DR4 associated autoimmune 
disease and family history of DR3/DR4 associated autoimmune disease. For diabetic 
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patients with 2≥ criteria, the sensitivity of having LADA was 90% and specificity 
71%.  The negative predictive value was 99% for a score that was 1≤, thus making 
this screening method useful in excluding LADA patients. When creating these 
criteria the patients included were 30-75 years old. LADA was defined in the same 
way as described earlier by the immunology of diabetes society with an exception that 
only GADA was used for autoantibody status.  
 
To better illustrate this complete diagnostic process, a diagnostic flowchart was made 
and is presented in figure 1. The flowchart shows that patients with 2≥ criteria can be 
screened for low or high GADA titers and divided into the subgroups LADA 1, 
LADA 2 or DM 2. The cut off value for a postive titer was ≥20U/ml and the cut off 
value chosen for the higher titer was ≥175U/ml. Type 2 diabetics had titers below 
20U/ml.  
 
There is an ongoing debate regarding which cut off values to use to differentiate 
between the LADA subtypes. The difference in treatment approach should guide this 
division of LADA and the two main points in the treatment considerations are the rate 
of insulin deficiency and the degree of insulin resistance. In a study a receiver 
operating characteristic (ROC) curve was used to decide on which GADA titer should 
be used as a cut off value to best categorize LADA into its two subtypes (23). The 
most distinct difference in rate of insulin deficiency and degree of insulin resistance 
was observed at a titer of 175U/ml with a sensitivity of 54.5% and a specificity of 
92.1%. Other studies have also used cut off values in the same range of 175-180U/ml 
(23, 24). 
 
GADA has proven to be the best and most sensitive autoantibody to diagnose LADA 
in several studies and therefore the most appropriate to screen for (25, 26). Antibody 
assays should be performed in a standardized manner with the a set specificity and 
sensitivity as suggested by the diabetes antibody standardization program. Many 
authors found that screening for multiple antibodies and not only GADA increases the 
diagnostic accuracy and better predicts the risk of progression to insulin dependence 
(27-29). It has been shown that the postivity of GADA and islet cell cytoplasmic 
autoantibodies (ICA) together yield a higher positive predicitve value of requiring 
insulin at an earlier rate compared to GADA alone, this being even more evident in 
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patients >45 years of age (25, 30). These results also comply with other studies in 
which patients with positivity of both ICA and GADA displayed a LADA 1 
phenotype with faster beta cell function decline (31, 32). Single GADA postivity in 
high titers also displayed the LADA 1 phenotype but not single ICA positivity(29, 
32). Patients with high titers of GADA more frequently had other autoantibodies 
positive as well (20). Therefore it could be satisfactory to use high GADA titers as a 
diagnostic marker for LADA in young patients that fulfill the other criteria presented 
in the flowchart shown in figure 1. For patients older than 50 years of age it could 
worth to perform additional antibody testing for ICA antibodies for a more accurate 
diagnosis. The presence of islet antigen-2 (IA-2) autoantibodies were highly 
predicitve of future insulin dependence but were expressed only in a few patients (26, 
33). C-peptide is endogenously released with insulin and functions as marker of beta 
cell function and can now be more cheaply measured in urine samples (34). C-peptide 
levels are now mostly used to differentiate between type 1 and 2 diabetes but it could 
function as a screening tool for LADA (35). 
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Diagnostic flowchart 
WHO criteria 
 
 
 
 
 
 
 
 
 
 
 
LADA clinically according to Immunology of diabetes society 
 
 
 
 
 
 
             Screening for LADA according to Fourlanos et al. 
 
 
 
 
 
 
 
 
                                                                                     
 
Yes	
G
A
D
A
<175U
/L 
 
Yes	
Yes	
No*	Yes	
Acute symptoms of diabetes: - polyuria - polydipsia - polyphagia - weight loss 
Any of the following positive: - FPG≥7.0mmol/L - Random venous glucose ≥11.1mmol/L - OGGT≥11.1mmol/L 
Insulin independent ≥6 months after diagnosis 
2≥ of the following: - BMI <25 kg/m2 - Age of onset < 50 years - Acute symptoms of diabetes - Personal or family history of DR3/DR4 
associated autoimmune disease 
DM	1	
DM	2		 LADA	1	LADA	2	 Figure	1.	*Second	confirmatory	(OGTT,	FPG)	test	necessary	
Age≥30y	
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Treatment strategies 
 
 
Insulin 
 
The slower onset of LADA to insulin deficiency opens up for an opportunity of a 
better planned treatment strategy. Insulin will eventually be necessary when the beta 
cell function dissapears in LADA. It has been hypothesized if early insulin treatment 
in the early stages could be helpful in slowing the progression to insulin deficiency. 
Early adminstration of exogenous insulin is thought to decrease the stress on the beta 
cells and thus perserving their secretory capacity. More active secretion of 
endogenous insulin also increases the body’s autoimmune response with beta cell 
damage as a consequence(36). Experimental diabetic non obese diabetic (NOD) mice 
had less amount of macrophage infiltrates in the exocrine pancreas if they were 
prophylactically treated with insulin compared to the non treated control (37).  
Exogenous insulin can promote acivation of T regs which have anti-inflammatory 
properties and can even induce remssion of the disease, discussed more in detail later 
in the review (38). In the diabetes prevention type 1 study, patients with first or 
second degree relatives with DM 1 were selected to estimate if oral insulin 
adminstration can be used in preventing the devlopment of DM 1 (39). In this 
randomized double blind placebo control study 372 patients, positive for islet cell 
antibodies, were split in equal sizes and either assigned to a treatment group that 
received 7.5mg/day of oral insulin or placebo. Median follow-up time was 4.3 years 
at which 43 patients in the treatment arm and 53 patients in the placebo arm had 
developed diabetes. The yearly incidence rates of diabetes were similar in both groups 
and oral insulin did not help in slowing down or preventing diabetes. A subgroup of 
treated patients with high titers of insulin autoantibodies (IAA) did have a delayed 
onset of diabetes but this relationship remains unclear since they generally had a 
slower onset compared to lower titer groups. The practical limitation of not being able 
to use subcutaneous insulin in these patients that still have not developed diabetes 
might affect the study outcome and questions the validity of this study. Oral insulin is 
partly destroyed by gastric acid and the full amount will not reach the intestines. The 
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main problems are a low bioavailbility and patient variation in pharmacodynamics 
(40). Other researchers have found that small doses of subcutaneous insulin can 
prevent and delay the progression to insulin dependence in LADA patients with high 
GADA titers and a preserved beta cell function at the beginning of the intervention 
(41, 42). Therefore benefits of using early insulin in a preventive manner might 
depend on route, timing and autoantibody status of LADA patients. If deciding on 
early intervention these factors should be considered. A swedish prospective study on 
LADA patients examined the effects of early insulin vs conventional treatment (43). 
They noticed a significantly better metabolic control, lower HbA1c and no difference 
in C-peptide levels in those treated with insulin.  
 
 
The studies done until now on early insulin in LADA and benefits in preserving beta 
cell function still show discrepancies and larger scale studies are essential to clarify 
the uncertainties.   
 
 
Oral hypoglycemics agents 
 
In the previously discussed studies, early insulin in High GADA titer patients could 
slow the progression to insulin dependence and improve metabolic control when 
compared to sulfonylurea treatment (41, 42). Similar conclusions regarding metablic 
control was observed by Cabrera-Rode et al. when using insulin as a monotherapy 
and not in combination with glibenclamide (44). In this study all the patients were 
intially ICA positive and after 1 year follow-up all the patients assigned to insulin 
monotherapy became ICA negative, in contrast to patients receiving combination 
therapy where all patients remained positive.  
 
Thiazolidinediones are suggested to decrease the destructive autoimmune 
inflammatory effects of T-cells on beta cells through activation of PPAR-g receptors 
present on T-cells (45, 46). Ciglitazone a PPAR-g-ligand have been show to increase 
the effect of T regs (47). A pilot study compared insulin treatment alone to insulin and 
rosiglitazone (48). They measured C-peptide levels 2h after a 75mg glucose meal 
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(PCP) every six months and at 12 and 18 months PCP remained stable in the 
combination group while decreasing in the insulin monotherapy group. This 
relationship was confirmed in a larger study where GADA levels were taken into 
account (49). Patients with GADA titers >175U/ml were again given insulin-only or 
insulin and rosiglitazone treatment. The C-peptide levels were significantly higher in 
the group with combination therapy after two years of follow-up but the gap 
diminshed and the difference became insignifiacnt after three years. There are proven 
adverse cardiovascluar effects from rosiglitazone and it has been taken off market in 
several countries. 
 
A more popular group of drugs are the DPP-4 inhibtors. The fact that they rarely 
cause hypoglycemia and generally have a better side-effect profile than sulfonylureas 
has lead to an increased interest on their effect on LADA as well.  In a open-labeled 
randomized control trial patients recently diagnosed with LADA were followed for a 
year. They either received insulin as monotherapy or in combination with 100mg/day 
sitagliptin (50). Compared to baseline, the C-peptide levels decreased significantly in 
the group treated only with insulin but remained steady in the patients additionally 
given sitagliptan. A post hoc study and a randomized double blind control study 
confirmed this beneficial effect off DDP-4 inhibitors on C-peptide levels (51, 52). In 
the former study patients were given saxagliptin or placebo and those on treatment 
had better sustained beta cell function 24 weeks after baseline. The same trend was 
observed in the two year double blind RTC were patients where given linagliptin or 
glimepiride. The mechanism of DPP-4 inhbitors on perservation of beta cell function 
in humans is still uncertain. Nonobese diabetic mice treated with DPP-4 inhibitors 
have shown reversal of their recent onset diabets through stimulation of beta cell 
replication and increase in T regs (53). Larger prospective studies are still necessary 
to uncover possible mechanisms in humans and to further explore the certainty of the 
benficial effects on beta cell preservation. 
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The role of regulatory T-cells (T regs) 
 
  
The immune supressor cells called T regs are important in the development of 
peripheral tolerance in diabetes. They are derived from the thymus and are the body’s 
natural defence against autoimmunity. A transcription factor called Foxp3 is 
expressed by T regs and this factor plays an important role in their development (54). 
The identification of T regs involves their expression of Foxp3. Decrease levels of T 
regs have been seen in mice with type 1 diabetes due to dysfunction of Foxp3. The 
same effect of low number T regs on development of autoimmune diabetes in humans 
have proven to be false in two studies (55, 56) but true in one study which showed 
decreased number of CD4+ T-cells with intermediate levels of CD 25 in early 
diagnosed LADA patients compared to healthy controls (57). Similar levels of T regs 
was measured for type 1 diabetics and in controls. The function could be more 
important than the number of T-regs in maintaining autoimmune tolerance (55). Both 
stable and instable T regs have been described (54). The goal of future and present 
therapy is to achieve enough functionally stable T regs and this can be done by adding 
ex-vivo expanded autologous polyclonal Tregs or converting the already instable cells 
into stable (54, 58). T regs instability can be caused by less response to certain 
cytokines due to decreased receptor affinities. GITR also a marker associated with T 
regs and its deficit implicated in their instability and poorer chance of survival (59). 
Instable T regs secrete lower amounts of anti-inflammatory cytokines (IL-35 and IL-
10) and their effector function potentiates. Epigentic changes in the Foxp3 region 
through demethylation can lead to instabiliy (54). Marek Trzonkowska et al. studied 
12 children diagnosed with T1D within 2 months and followed them for one year 
after they received autologous polyclonal T regs (60). They were compared at 4 and 
12 months to 10 controls matched for sex, age and duration of the disease. Half of the 
12 patients in the treatment arm received two doses of T regs and the rest one dose. 
Less insulin dependence, lower HbA1c and higer fasting C-peptide levels was seen in 
treatment vs control group at 4 and 12 months. The C-peptide levels were even higher 
for the patients treated with two doses compared to those treated with one dose. Eight 
of 12 patients in the treatment group had remission of their diabetes vs none in the 
control group. Unfortunately readministration with a subsequent dose had a decreased 
effect and the positive protective effects wore of eventually as the concentrations of T 
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regs in plasma decreased. Generally there were no serious adverse effect in the 
treament arm. Another similar study on T1D adults with less promising resluts was 
performed by Bluestone et al. in a phase 1 trial. They investigated the effect and 
safety of adding autologous ex-vivo expanded Tregs in 14 recently diagnosed adult 
T1D patients (61). The patients were divided in 4 cohort groups with a follow-up time 
of 104-182 weeks between the groups. A decrease of >50% in C-peptide levels 
occured in two of the cohorts after 78 weeks but remained the same in the other two 
cohorts even after 2 years. Upon completion there was no infusion reactions or other 
serious adverse effects short-term, proving the safety of this approach and 
encouraging a phase 2 trial with increased number of patients to get more reliable 
results.  
A possible reason for the added T regs not providing the full effect in the adult 
patients the start of treatment was done several weeks post-diagnosis for them and 
within two weeks for the children. Marek Trzonkowska et al. stated that higher intial 
C-peptide was correlated with a longer remission time. Pharmacotherapy with CD3 
monoclonal antibodies in some studies have maintained C-peptide levels in recent 
onset DM 1 patients treated with them (62-64). CD3 antibodies have a potential to 
restore stability in T regs that are unstable and promote an increase number of normal 
T regs (65).  
 
Discussion   
 
The current knowledge about LADA is still lacking with no clear treatment 
guidelines. There is a need for standardization of LADA to enable proper analysis of 
data and better comparison of results between studies. The heterogenous nature of this 
disease has prevented the realization of this even though LADA has by many been 
recognized as seperate type of diabetes for some time now. Others still consider 
LADA as a part of a spectrum from DM 1 to DM 2 with LADA 1 and LADA 2 in 
between. This assumption could lead to less research being done on LADA and in 
turn negatively affect this group of patients. Incorrect treatment of LADA patients 
with hypoglycemics as they were type 2 diabetics can lead to long term 
complications. They are more often in need of stricter disease surveillance to maintain 
proper metabolic control and more often present with other concomitant autoimmune 
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diseases. This group should be treated with insulin earlier to achieve better glycemic 
control and less beta cell failure. The timing of insulin and gliptin treatments could be 
crucial for perserving beta cell function for as long as possible. More and larger long 
term prospective studies are needed to validate the results in the smaller studies with 
short follow-up time. The studies examined in this review contain a lot of systematic 
errors and the analyses compared are not done with identical methods and criterias. 
The difference in LADA between various ethnicities need to be further elucidated as 
well. High GADA postivity seem to be a constant predictor of LADA regardless of 
ethnicity (27, 66), but response to various treatments might differ. DPP-4 inhibtors 
and acarbose have proven more efficacious in asian population than in caucasian (67, 
68). If this is related to ethnicity, environmental exposures in each geographic area or 
a combination of both remains unknown.   
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Conclusion 
 
Currently, without a clear marker of exact diabetes classification in slowly 
progressive autoimmune diabetes in adults, the best that can be done for recently 
diagnosed patients is to carefully evaluate their diabetes subtype in a meticulous 
manner so that the right therapeutic approach can be chosen. Improper glucose control 
in incorrectly diagnosed DM 2 patients can eventually lead to long term 
complications.  
 
For LADA patients with high GADA titers and preserved beta cell function at 
diagnosis, early insulin treatment might prevent further beta cell detoriation. 
Sulfonylureas have an adverse effect on C-peptide levels, while DPP-4 inhibitors 
have been shown to sustain them and are thus recommended. Immunotherapy with 
autologous polyclonal Tregs and CD3 antbodies have both shown promising results 
regarding C-peptide levels although the studies conducted have been small with few 
participants.  
 
The need for studies of larger scale is essential to develop better defined criteria, 
guidelines and treatment approaches in this group of underdiagnosed patients. The 
present research implicates that these issues should not be neglected. 
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